Drugs / Enoxheparin
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT02715492 | Oct 2018 → Dec 2022 | hepatocellular carcinoma | Tanta University | Unknown | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Enoxheparin | “(Enoxheparin) 1 IU/kg per dose twice daily for 2 weeks from the 1st day of TACE” NCT02715492 ↗ |